“Dupilumab Decreases Blood Biomarkers in Adolescents With Moderate-to-Severe Atopic Dermatitis: Data From a Phase 3 Trial (LIBERTY AD ADOL)”. SKIN The Journal of Cutaneous Medicine, vol. 4, no. 5, Sept. 2020, p. s49, https://doi.org/10.25251/skin.4.supp.48.